Now showing items 1-2 of 2

    • Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? 

      O'Connor, JPB; Jayson, GC (2012-12)
      The management of solid tumors has been transformed by the advent of VEGF pathway inhibitors. Early clinical evaluation of these drugs has used pharmacodynamic biomarkers derived from advanced imaging such as dynamic MRI, ...
    • Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. 

      Samson, A; Bentham, MJ; Scott, K; Nuovo, G; Bloy, A; Appleton, E; Adair, RA; Dave, R; Peckham-Cooper, A; Toogood, G; Nagamori, S; Coffey, M; Vile, R; Harrington, K; Selby, P; Errington-Mais, F; Melcher, A; Griffin, S (2018-03)
      Objective Oncolytic viruses (OVs) represent promising, proinflammatory cancer treatments. Here, we explored whether OV-induced innate immune responses could simultaneously inhibit HCV while suppressing hepatocellular ...